Annexin A3 is associated with a poor prognosis in breast cancer and participates in the modulation of apoptosis in vitro by affecting the Bcl-2/Bax balance

Experimental and Molecular Pathology

Volumn 95, Issue 1, 2013, Pages 23-31

  Zeng, Chao ^a   Ke, Zunfu ^b   Song, Yulan ^c   Yao, Yunhong ^a   Hu, Xinrong ^a   Zhang, Miao ^d   Li, Hongmei ^a   Yin, Jinbao ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^d Xin Hui Maternity and Child Health Care Hospital   (China)

Author keywords

Annexin A3; Apoptosis; Bcl 2 Bax balance; Breast cancer; Prognosis

Indexed keywords

GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL FEATURE; COLONY FORMATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT OUTCOME; TUMOR VOLUME;

ANNEXIN A3; APOPTOSIS; BCL-2/BAX BALANCE; BREAST CANCER; PROGNOSIS;

ADULT; AGED; ANNEXIN A3; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 84878139457     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.04.002     Document Type: Article

References (25)

1. Bae S.M., Lee C.H., Cho Y.L., Nam K.H., Kim Y.W., Kim C.K., Han B.D., Lee Y.J., Chun H.J., Ahn W.S. Two-dimensional gel analysis of protein expression profile in squamous cervical cancer patients. Gynecologic Oncology 2005, 99:26-35.
2. Bai X.F., Ni X.G., Zhao P., Liu S.M., Wang H.X., Guo B., Zhou L.P., Liu F., Zhang J.S., Wang K., Xie Y.Q., Shao Y.F., Zhao X.H. Overexpression of annexin I in pancreatic cancer and its clinical significance. World Journal of Gastroenterology 2004, 10:1466-1470.
3. 2+/GTP sensor in exocytotic secretion. Proceedings of the National Academy of Sciences 1996, 93:10797-10802.
4. Chen R., Brentnall T.A., Pan S., Cooke K., Moyes K.W., Lane Z.L., Crispin D.A., Goodlett D.R., Aebersold R., Bronner M.P. Quantitative pmteomic analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Molecular & Cellular Proteomics 2007, 6:1331-1342.
5. Coleman R.E. Future directions in the treatment and prevention of bone metastases. American Journal of Clinical Oncology 2002, 25:32-38.
6. Debatin K.M. Apoptosis pathways in cancer and cancer therapy. Cancer Immunology, Immunotherapy 2004, 53:153-159.
7. Domoto T., Miyama Y., Suzuki H., Teratani T., Arai K., Sugiyama T., Takayama T., Mugiya S., Ozono S., Nozawa R. Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Science 2007, 98:77-82.
8. Esposito I., Penzel R., Chaib-Harrireche M., Barcena U., Bergmann F., Riedl S., Kayed H., Giese N., Kleeff J., Friess H., Schirmacher P. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. The Journal of Pathology 2006, 208:673-685.
9. Gerke V., Moss S.E. Annexins: from structure to function. Physiological Reviews 2002, 82:331-371.
10. 2+ signalling to membrane dynamics. Nature Reviews Molecular Cell Biology 2005, 6:449-461.
11. Kollermann J., Schlomm T., Bang H., Schwall G.P., Eichel-Streiber C.V., Simon R., Schostak M., Huland H., Berg W., Sauter G., Klocker H., Schrattenholz A. Expression and prognostic relevance of Annexin A3 in prostate cancer. European Urology 2008, 54:1314-1323.
12. Liu Y.F., Xiao Z.Q., Li M.X., Li M.Y., Zhang P.F., Li C., Li F., Chen Y.H., Yi H., Yao H.X., Chen Z.C. Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. The Journal of Pathology 2009, 217:54-64.
13. Madoz-Gurpide J., Lopez-Serra P., Martínez-Torrecuadrada J.L., Sanchez L., Lombardía L., Casal J.I. Proteomics-based validation of genomic data. Molecular & Cellular Proteomics 2006, 5:1471-1483.
14. Masaki T., Tokuda M., Ohnishi M., Watanabe S., Fujimura T., Miyamoto K., Itano T., Matsui H., Arima K., Shirai M., Maeba T., Sogawa K., Konishi R., Taniguchi K., Hatanaka Y., Hatase O., Nishioka M. Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology 1996, 24:72-81.
15. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Reviews. Cancer 2002, 2:584-593.
16. Paulson K.E., Rieger-Christ K., McDevitt M.A., Kuperwasser C., Kim J., Unanue V.E., Zhang X., Hu M., Ruthazer R., Berasi S.P., Huang C.Y., Giri D., Kaufman S., Dugan J.M., Blum J., Netto G., Wazer D.E., Summerhayes I.C., Yee A.S. Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer. Cancer Research 2007, 67:6136-6145.
17. Pena-Alonso E., Rodrigo J.P., Parra I.C., Garcia Pedrero J.M., Nieto C.S., Fresno M.F., Morgan R.O., Fernandez M.P. Annexin A2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck squamous cell carcinoma. Cancer Letters 2008, 263:89-98.
18. Pencil S.D., Toth M. Elevated 1evels of annexin I protein in vitro and in vivo in rat and human mammary adenocarcinoma. Clinical & Experimental Metastasis 1998, 16:113-121.
19. Perretti M., Gavins F.N. Annexin 1: an endogenous anti-inflammatory protein. News in Physiological Sciences 2003, 18:60-64.
20. Raynal P., Pollard H.B. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochimica et Biophysica Acta 1994, 1197:63-93.
21. Stewart J., Fleshner N., Cole H., Sweet J. Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study. Journal of Clinical Pathology 2007, 60:773-780.
22. Tan Y., Meng H.P., Teng F.M., Jia X.S., Wu H.R. Effect of miRNA interference to annexinA3 gene on growth of human gallbladder cancer cells. Chin Hepatobiliary Surgery 2010, 16:853-856.
23. Wamunyokoli F.W., Bonome T., Lee J.Y., Feltmate C.M., Welch W.R., Radonovich M., Cindy P.M., Brady J., Hao K., Berkowitz R.S., Mok S., Birrer M. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clinical Cancer Research 2006, 12:690-700.
24. Yan X.D., Yin J., Yao H.Y., Mao N., Yang Y.L., Pan L.Y. Increased expression of Annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Research 2010, 70:1616-1624.
25. Zimmermann U., Woenckhaus C., Teller S., Venz S., Langheinrich M., Protzel C., Maile S., Junker H., Giebel J. Expression of annexin AI in conventional renal cell carcinoma (CRCC) correlates with tumour stage, Fuhrman grade, amount of eosinophilic cells and clinical outcome. Histology and Histopathology 2007, 22:527-534.